The lancet oncology
-
The lancet oncology · Nov 2015
Randomized Controlled Trial Multicenter Study Comparative StudyBusulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial.
The standard busulfan-cyclophosphamide myeloablative conditioning regimen is associated with substantial non-relapse mortality in patients older than 40 years with acute myeloid leukaemia who are undergoing allogeneic stem-cell transplantation. Because the combination of busulfan plus fludarabine has been proposed to reduce non-relapse mortality, we aimed to compare this treatment with busulfan plus cyclophosphamide as a preparative regimen in these patients. ⋯ Agenzia Italiana del Farmaco.
-
The lancet oncology · Nov 2015
Comparative StudyCancer incidence in indigenous people in Australia, New Zealand, Canada, and the USA: a comparative population-based study.
Indigenous people have disproportionally worse health and lower life expectancy than their non-indigenous counterparts in high-income countries. Cancer data for indigenous people are scarce and incidence has not previously been collectively reported in Australia, New Zealand, Canada, and the USA. We aimed to investigate and compare, for the first time, the cancer burden in indigenous populations in these countries. ⋯ International Agency for Research on Cancer-Australia Fellowship.